韩国政府遴选6个AI医疗器械商业化支持联盟，JLK和Lunit入选

The South Korean government will support six consortiums in the fields of brain disease prediction, cancer diagnosis, and cardiovascular prediction to accelerate the clinical adoption of artificial intelligence (AI) medical devices.
The Ministry of Health and Welfare and the Korea Health Industry Development Institute announced on the 4th that they had held a launch briefing and business agreement ceremony for the Fast-Track Commercialization Support Program for AI Applications, and selected six operating consortiums. The core of the program is to support clinical validation of AI products, accumulation of real-world data, and marketing to accelerate the commercialization of AI medical devices that have been blocked from entering the market. Until now, even when excellent AI medical devices were developed in Korea and received approval from the Ministry of Food and Drug Safety, there were high barriers to actual adoption by medical institutions and application of health insurance reimbursement. Each consortium, consisting of a lead company and two or more medical institutions, will receive government funding of up to about 19 million won over two years.
In the brain disease field, the JLK (322510) consortium will introduce its brain perfusion and cerebral infarction analysis AI to the neurology departments of 22 hospitals, including Hallym University Sacred Heart Hospital and Seoul National University Bundang Hospital, to demonstrate its effectiveness in improving the prognosis of acute stroke patients and its economic value. The Heuron consortium will collaborate with the neurology departments of three hospitals, including Yonsei University Severance Hospital, to conduct clinical validation using an MRI-based Parkinson's disease diagnostic support AI, reducing the burden of unnecessary positron emission tomography (PET) scans and improving diagnostic accuracy.
In the cancer diagnosis field, the Lunit (328130) consortium will apply its chest X-ray and breast cancer diagnostic support AI to 10 hospitals, including Seoul National University Hospital, Kangbuk Samsung Hospital, and Konkuk University Hospital, to accumulate 250,000 cases of real-world data and pursue entry into the insurance reimbursement system. The Prevenotics consortium will introduce its real-time gastroscopy AI analysis solution to the gastroenterology departments of seven large hospitals, including Seoul National University Hospital and Severance Hospital, to demonstrate its effectiveness in improving the diagnostic accuracy of gastric cancer precursor lesions and reducing unnecessary biopsies.
In the cardiovascular prediction field, the Synergy AI consortium will apply its biosignal analysis AI to the cardiology departments of 15 university hospitals, including Seoul St. Mary's Hospital and Korea University Guro Hospital, to verify the effectiveness of arrhythmia risk prediction. The Mediwhale consortium will collaborate with Yonsei University Severance Hospital and Hanyang University Guri Hospital to demonstrate the safety and effectiveness of its fundus imaging-based cardiovascular risk assessment AI, aiming to have cardiovascular risk assessment for chronic disease patients and preoperative patients registered for reimbursement.
Sung Chang-hyun, Director General of the Health Industry Policy Bureau at the Ministry of Health and Welfare, said, "This project will serve as a key catalyst to help AI digital medical devices go beyond simple technology development and contribute to public health in actual clinics." He added, "We will support excellent AI medical devices to successfully settle in the field, and ensure that the data accumulated and market entry experience gained from the project can spread throughout the entire industry."